Expand CELC Menu
CELC MENU

CELC Latest Press Releases

-- December 11, 2025 --

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium Globe Newswire 2:35 PM

-- November 26, 2025 --

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium Globe Newswire 4:05 PM
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference Globe Newswire 7:05 AM

-- November 17, 2025 --

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer Globe Newswire 4:05 PM

-- November 12, 2025 --

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM

-- November 5, 2025 --

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call Globe Newswire 7:05 AM

-- November 4, 2025 --

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference Globe Newswire 7:05 AM

-- October 18, 2025 --

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer Globe Newswire 4:30 AM
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ("mCRPC") Globe Newswire 4:30 AM
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial Globe Newswire 4:30 AM

-- September 22, 2025 --

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress Globe Newswire 9:15 AM

-- September 9, 2025 --

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance Globe Newswire 4:01 PM

-- August 31, 2025 --

Celcuity Inc. Earnings Call: Clinical Progress and Financial Fortification TipRanks 8:37 PM

-- August 27, 2025 --

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program Globe Newswire 4:05 PM

-- August 14, 2025 --

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM

-- August 7, 2025 --

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call Globe Newswire 7:05 AM

-- July 30, 2025 --

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants Globe Newswire 6:30 AM

-- July 28, 2025 --

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock Globe Newswire 4:02 PM
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes